Vijay Goli, MD
Urology · Las Vegas, NVNPI 1043305972
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Uroviu Corporation at 43.2% of the total. Reporting peaked in 2022 at $40,625 and has fallen 67.8% since, to $13,084 in 2025. Among urology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 554 payments — averaging $190.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Uroviu Corporation$45K
- Palette Life Sciences, Inc.$12K
- Pfizer$6K
- Bioprotect Medical, Inc.$5K
- Ethicon Endo-surgery Inc.$4K
- Avyxa Pharma, LLC$3K
- plus $29K from 54 others
Across 39 payments — averaging $11,109 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$260K
- AbbVie$144K
- Urovant Sciences Inc$14K
- Uroviu Corporation$12K
- Sumitomo Pharma America, Inc.$4K
What the payments were for
- Consulting fees$61,34758%
- Speaking & faculty fees$9,1029%
- Travel & lodging$6,1986%
- Food & beverage$28,42527%
- Education$2120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Uro-G Flexible Cystoscope$45,324
- Deflux$11,011
- XTANDI$7,577
- Monarch Platform$4,510
- BIOPROTECT BALLOON IMPLANT SYSTEM$4,492
- PROVENGE$2,595
- ILLUCCIX$2,091
- AquaBeam Robotic System$1,332
- TITAN$1,014
- JELMYTO$996
- REZUM$792
- NOCDURNA$722
- Nanoknife$703
- UroLift$480
- Solesta$479
- SPACEOAR$414
- iTIND System$384
- Lithotripters & Accessories$382
- Optilume BPH Drug Coated Balloon Catheter$328
- Axumin$325
How this compares
$105,283 in reported general payments places this provider in the 95th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 53 | $64,260 |
| GemtesaVibegron | 13 | $11,741 |
| Tamsulosin Hcl | 928 | $11,596 |
| Cephalexin | 188 | $6,615 |
| Fosfomycin Tromethamine | 11 | $6,022 |
| NitrofurantoinNitrofurantoin Macrocrystal | 79 | $3,830 |
| Ciprofloxacin Hcl | 1,546 | $3,161 |
| Oxybutynin Chloride | 80 | $2,106 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 444 | $2,068 |
| Solifenacin Succinate | 15 | $2,024 |
| Testosterone Cypionate | 54 | $2,024 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 64 | $1,748 |
| Testosterone | 12 | $1,744 |
| Estradiol | 18 | $1,116 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 39 | $898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,004 | $64,26053 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $375 | $11,74113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 63 urology providers in Nevada.
Other urology in Las Vegas
- Joel AbbottLas Vegas$69K
- Victor GrigorievLas Vegas$59K
- Omid LesaniLas Vegas$27K
- Joseph CandelaLas Vegas$24K
- Lawrence NewmanLas Vegas$22K
- Michael VerniLas Vegas$16K
- Mulugeta KassahunLas Vegas$13K
- Jason ZommickLas Vegas$12K
- Ilya GorbachinskyLas Vegas$11K
- Sheldon FreedmanLas Vegas$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.